Chlamydia Pneumoniae CdsL Regulates CdsN ATPase Activity, and Disruption with a Peptide Mimetic Prevents Bacterial Invasion by Chris B. Stone et al.
www.frontiersin.org February 2011 | Volume 2 | Article 21 | 1
Original research article
published: 14 February 2011
doi: 10.3389/fmicb.2011.00021
Chlamydia pneumoniae CdsL regulates CdsN ATPase activity, 
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Chlamydiae are obligate intracellular pathogens that likely require type III secretion (T3S) to 
invade cells and replicate intracellularly within a cytoplasmic vacuole called an inclusion body. 
Chlamydia pneumoniae possess a YscL ortholog, CdsL, that has been shown to interact with the 
T3S ATPase (CdsN). In this report we demonstrate that CdsL down-regulates CdsN enzymatic 
activity in a dose-dependent manner. Using Pepscan epitope mapping we identified two separate 
binding domains to which CdsL binds viz. CdsN221–229 and CdsN265–270. We confirmed the binding 
domains using a pull-down assay and showed that GST–CdsN221–270, which encompasses these 
peptides, co-purified with His–CdsL. Next, we used orthology modeling based on the crystal 
structure of a T3S ATPase ortholog from Escherichia coli, EscN, to map the binding domains 
on the predicted 3D structure of CdsN. The CdsL binding domains mapped to the catalytic 
domain of the ATPase, one in the central channel of the ATPase hexamer and one on the outer 
face. Since peptide mimetics have been used to disrupt essential protein interactions of the 
chlamydial T3S system and inhibit T3S-mediated invasion of HeLa cells, we hypothesized that 
if CdsL–CdsN binding is essential for regulating T3S then a CdsN peptide mimetic could be 
used to potentially block T3S and chlamydial invasion. Treatment of elementary body with a 
CdsN peptide mimetic inhibited C. pneumoniae invasion into HeLa cells in a dose-dependent 
fashion. This report represents the first use of Pepscan technology to identify binding domains for 
specific T3S proteins viz. CdsL on the ATPase, CdsN, and demonstrates that peptide mimetics 
can be used as anti-virulence factors to block bacterial invasion.
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close association with the inclusion membrane, suggesting a need 
for active T3S in RBs. This interaction with the inclusion membrane 
allows the RB to communicate with the host cell via T3S, allowing 
the Chlamydia to commandeer host cell pathways to obtain lipids, 
cholesterol, and other nutrients crucial for its growth and repli-
cation, and also to prevent phagosome endosome fusion (Wylie 
et al., 1997; Hoare et al., 2008; Scidmore and Hackstadt, 2008). 
Following inclusion body growth to accommodate replicating RBs, 
an unknown signal (possibly quorum sensing) triggers the detach-
ment of RBs from the membrane and subsequent re-assortment 
into infectious EBs. The EBs then exit the host cell either by cell 
lysis or through extrusion, a packaged release mechanism which 
leaves the host cell intact (Hybiske and Stephens, 2007).
Type III secretion is a virulence mechanism commonly used 
by Gram-negative bacteria to directly translocate effector proteins 
from the bacterial cytoplasm to the host cell cytoplasm in a sin-
gle step, through the use of a syringe-like apparatus termed an 
injectisome (Galan and Collmer, 1999; Ghosh, 2004; Galan and 
Wolf-Watz, 2006). The injectisome is constructed of 20–25 proteins 
spanning the inner membrane, periplasm, and outer membrane, 
extending into the extracellular milieu to allow for host cell sensing 
and contact. Upon host cell contact, the T3S injectisome  apparatus 
IntroductIon
Chlamydia pneumoniae is an obligate, intracellular Gram-negative 
bacteria that has been associated with community acquired pneu-
monia (Clifton et al., 2004), atherosclerosis (Grayston, 2000), 
arthritis (Ardeniz et al., 2005), and Alzheimer’s disease (Balin 
et al., 2008). The members of the genus Chlamydia all share a 
unique, biphasic life-cycle that is initiated by attachment of the 
metabolically quiescent elementary body (EB) to the host cell. The 
association between the EB and the host cell membrane is poorly 
understood, but glycosaminoglycans may be involved (Chen and 
Stephens, 1997). Once attached to the host cell, type III secretion 
(T3S) is utilized to inject the translocated actin recruitment pro-
tein (TARP) to facilitate bacterial internalization into a plasma-
membrane derived vacuole, termed an inclusion (Clifton et al., 
2004; Lane et al., 2008). The MEK–ERK and PI 3-kinase pathways 
of the host cell are also involved in bacterial uptake, and are possibly 
targets of other T3S effectors translocated across the cytoplasmic 
membrane upon EB contact and binding to host cells (Coombes 
and Mahony, 2002; Carabeo et al., 2004; Subtil et al., 2004). Once 
inside the host cell the remainder of the life-cycle occurs inside 
the inclusion body where EBs differentiate into the metabolically 
active, non-infectious reticulate bodies (RB). The RB remains in 
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CdsN (Bernard et al., 2004; Teeling et al., 2006; Timmerman et al., 
2007). We found that CdsN possesses two distinct binding domains 
for CdsL, one to potentially mediate the tethering function and 
the other to mediate the down-regulation function. We also show 
that a CdsN peptide acts as a peptide mimetic preventing bacterial 
invasion. This is the first report to identify binding domains for a 
T3S ATPase regulating protein and the use of a peptide mimetic as 
a novel antimicrobial agent to potentially target T3S.
MaterIals and Methods
expressIon plasMIds
Chlamydia pneumoniae CWL029 (VR1310:ATCC; GenBank acces-
sion No. AE001363) was the strain used to isolate genomic DNA 
for cloning and protein expression. Full length cdsL and cdsN were 
amplified from CWL029 using AttB-containing primers (Gateway; 
Invitrogen). The amplified products were cloned into pDONR
201
 
(Gateway; Invitrogen) to generate pENT vectors. The pENT vectors 
were then used in LR reactions (Gateway; Invitrogen) to produce 
pEX vectors containing the genes of interest. We used either pEX
17
 
(N-terminal His-tag) or pEX
15 
(N-terminal GST-tag) vectors for our 
protein expression. All constructs were confirmed by sequencing at 
the Molecular Biology Facility at McMaster University.
proteIn expressIon
All constructs were expressed in E. coli Rosetta pLysS. Expression 
plasmids were used to transform E. coli Rosetta pLysS and 
plated on LB plates containing 100 µg/mL ampicillin. LB broth 
(750 mL), containing antibiotics, was then inoculated with 12 mL 
of an overnight culture and grown at 37°C until they reached an 
optical density (OD)
600
 of approximately 0.8. Cultures were then 
cooled on ice to 20°C and induced with 0.2 mM of isopropyl 
β-d-thiogalactopyranoside (IPTG). Cultures were then incubated 
at 23°C for 2 h and bacteria were harvested by centrifugation at 
6500×g for 10 min in a Sorvall RC-5B centrifuge and washed with 
ice-cold phosphate-buffered saline (PBS). Bacteria containing His-
tagged protein were resuspended in either Binding Buffer (50 mM 
potassium phosphate pH 7.2, 150 mM KCl, 1 mM MgCl
2
) when 
used in GST pull-downs, or Nickel A buffer (20 mM Tris pH 7.0, 
0.02% β-mercaptoethanol, 400 mM KCl, 1% Triton X-100) when 
used in ATPase activity assays, while the bacteria containing GST-
tagged protein were resuspended in PBS and stored at −20°C until 
further use.
purIfIcatIon of recoMbInant proteIns
Escherichia coli pellets containing over-expressed His- or GST-tagged 
proteins were thawed on ice and sonicated using a Fischer Scientific 
Sonic Dismembrator Model 100, followed by centrifugation at 
20,000×g for 40 min to remove insoluble material. Supernatants 
containing His-tagged protein for use in GST pull-down assays were 
stored at 4°C. GST-tagged protein for use in GST pull-down assays 
were bound to 300 µL of glutathione beads overnight at 4°C, then 
blocked overnight in Tris Buffered Saline with 0.1% Tween-20 and 
4% BSA and stored at 4°C until use. His- and GST-tagged protein 
supernatants for use in ATPase activity assays were filtered through 
0.45 µm acrodisc filters (Pall Corporation) and purified on either 
a 1-mL GSTrap FF column (GE Healthcare) or a 1-mL HisTrap 
HP column (GE Healthcare). For GST-tagged protein, columns 
injects two translocator proteins into the host cell membrane to 
form the translocon, a molecular pore through which secreted pro-
teins can enter the host cell (Goure et al., 2004). Despite the fact 
that Chlamydia possesses a full repertoire of T3S genes scattered 
throughout the genome on at least 10 distinct operons, a systematic 
study of the injectisome has yet to be undertaken as chlamydial spe-
cies are genetically intractable (Hefty and Stephens, 2007). Recent 
reports have identified a few T3S structural and effector proteins, 
providing some understanding of the Chlamydia T3SS. Our labo-
ratory has shown that CdsD, a unique protein orthologs to YscD 
that contains two fork-head associated domains, interacts with the 
predicted C. pneumoniae ATPase tethering protein, CdsL, as well 
as CdsQ, a putative multi-cargo transport protein (Johnson et al., 
2008; Spaeth et al., 2009). We extended these findings to show that 
CdsN also binds to this complex, and interacts independently with 
CdsD, CdsL, and CdsQ (Stone et al., 2008). Betts et al. (2008) have 
also recently identified the C. trachomatis CT666 gene encoding 
CdsF, the needle filament protein of the injectisome. The role of a 
few effector proteins of C. pneumoniae have been recently discov-
ered. Cpn0585 is found in the inclusion membrane and interacts 
with Rab 1, 10, and 11, possibly recruiting these ATPases to the 
inclusion membrane (Cortes et al., 2007). Cpn0827 is a second 
effector protein that is detectable in the inclusion membrane at 
20 hpi (Hermann et al., 2006). The Chlamydia protein associating 
with death domains (CADD) is a conserved effector known to 
interact with TNF family receptors (Stenner-Liewen et al., 2002). 
Recent biophysical evidence has also been presented by Markham 
et al. (2009) suggesting that the C. trachomatis protein CT584 could 
function as the needle tip protein, which is imperative for host cell 
sensing and translocator insertion into the host cell membrane.
Type III secretion ATPases are believed to be assembled as a 
hexameric ring at the basal body of the injectisome and play a role 
in delivery of effector proteins through the injectisome (Zarivach 
et al., 2007). Several T3S ATPases have been partially characterized, 
including EscN from Escherichia coli (Andrade et al., 2007), YscN 
from Yersinia (Blaylock et al., 2006), and InvC from Salmonella 
(Akeda and Galan, 2004), although the ability of the T3S ATPase to 
coordinate numerous protein interactions has not been explored. 
These ATPases have been shown to have significant sequence 
orthology to the β subunit of the F0F1 ATPase, and to hydrolyze 
ATP. Not only are these ATPases important for providing energy for 
protein transport, but they are believed to play a role in unfolding 
the effector proteins before translocation, which may be accom-
plished by releasing the chaperone from its cognate effector protein 
(Akeda and Galan, 2005). In Yersinia, the ATPase tethering protein 
YscL localizes the ATPase to the inner membrane, potentially by 
performing a function similar to that of the gamma-stalk of the 
F
0
F
1
 ATPase (Pallen et al., 2006). YscL has also been shown to play 
a role in regulation of the ATPase activity by down-regulating enzy-
matic activity (Blaylock et al., 2006). The quaternary structure of 
ATPase, viz. the hexamer, has been associated with enhanced enzy-
matic activity and most likely reflects the native conformation of 
this protein.
In this report we show that CdsL down-regulates the enzymatic 
activity of CdsN. We utilized Pepscan epitope mapping to deter-
mine where CdsL binds to CdsN, and used an orthology modeling 
approach to map this domain onto the predicted 3D structure of 
www.frontiersin.org February 2011 | Volume 2 | Article 21 | 3
Stone et al. CdsN possesses discreet binding domains for CdsL
order to reconstruct conformational epitopes, using Chemically 
Linked Peptides on Scaffolds (CLIPS) technology (Timmerman 
et al., 2007). For example, the single looped peptides are synthesized 
containing a dicysteine, which was cyclized by treating with alpha, 
α′-dibromoxylene, and the size of the loop is varied by introduc-
ing cysteine residues at variable spacing. If other cysteines besides 
the newly introduced cysteines are present, they are replaced by 
alanine. The side-chains of the multiple cysteines in the peptides 
are coupled to CLIPS templates by reacting onto credit-card for-
mat polypropylene Pepscan cards (455 peptide formats/card) 
with a 0.5-mM solution of CLIPS template such as 1,3-bis (bro-
momethyl) benzene in ammonium bicarbonate (20 mM, pH 7.9)/
acetonitrile [1:1(v/v)]. The cards are gently shaken in the solution 
for 30–60 min while completely covered in solution. Finally, the 
cards are washed extensively with excess of H
2
O and sonicated in 
disrupt-buffer containing 1% SDS/0.1% β-mercaptoethanol in PBS 
(pH 7.2) at 70°C for 30 min, followed by sonication in H
2
O for 
another 45 min. The binding of antibody or labeled protein/peptide 
to each peptide is tested in a Pepscan-based ELISA. The 455-well 
credit-card format polypropylene cards containing the covalently 
linked peptides are incubated with peptide solution for example 
consisting of 1 µg/mL diluted in blocking solution, for example 4% 
horse serum, 5% ovalbumin (w/v) in PBS/1% Tween. After washing, 
the peptides are incubated with a monoclonal mouse anti-His-
tag antibody (1/1000, Novagen, 70796-3) and subsequently after 
washing with a rabbit-anti-mouse antibody peroxidase conjugate 
(1/1000, Southern Biotech, 6175-05) for 1 h at 25°C. After washing, 
the peroxidase substrate 2,2′-azino-di-3-ethylbenzthiazoline sul-
fonate (ABTS) and 2 µL of 3% H
2
O
2
 are added. After 1 h, the color 
development is measured. The color development is quantified with 
a charge coupled device (CCD)-camera and an image processing 
system. The raw-data are optical values obtained by a CCD-camera. 
The values mostly range from 0 to 3000, a log scale similar to 1–3 
of a standard 96-well plate ELISA-reader. First the CCD-camera 
makes a picture of the card before peroxidase coloring and then 
again a picture after the peroxidase coloring. These two pictures 
are subtracted from each other which results in the data which is 
called raw-data. This is copied into the Peplab™ database. Then the 
values are copied to excel and this file is labeled as raw-data file. One 
follow-up manipulation is allowed. Sometimes a well contains an 
air-bubble resulting in a false-positive value, the cards are manu-
ally inspected, and any values caused by an air-bubble are scored 
as 0. 3D structure prediction was performed using 3D-JIGSAW 
(http://www.bmm.icnet.uk/∼3djigsaw/). Modeling was then per-
formed using PYMOL software.
peptIde desIgn and entry Into ebs
Based on the Pepscan epitope mapping of CdsN, two domains 
were found that mediate the interaction between CdsN and CdsL. 
The smaller of the two domains (residues 265–279), corresponding 
to TRFARA, was chosen to create a peptide mimetic compound. 
We synthesized the TRFARA peptide with a N-terminal mem-
brane transport sequence (MTS), YGRKKRRQRRR (Efthymiadis 
et al., 1998). We also extended the CdsN sequence flanking the 
TRFARA peptide to ensure the entire binding domain was 
included, and flanked the peptide with cysteine residues to assist 
with any disulfide bonding that may be required for  binding. 
were washed with PBS + 0.1% Tween until the flow-through had 
an OD
280
 of less than 0.005. GST-tagged protein was then eluted 
off the beads using 1.5 µg/µL reduced glutathione (Sigma) and 
dialyzed against activity buffer (50 mM Tris–HCl pH 7.0, 5 mM 
MgCl
2
, 10 mM KCl). Purity was confirmed using SDS–PAGE and 
Coomassie blue staining. For His-tagged proteins, columns were 
washed with increasing imidazole concentrations and eluted with 
300 mM imidazole then dialyzed into activity buffer. Purity was 
confirmed using SDS–PAGE and Coomassie blue staining.
cdsn enzyMatIc actIvIty down-regulatIon experIMents
ATP hydrolysis by GST–CdsN purified from GSTrap columns was 
measured using a malachite green assay (R&D Systems) which 
measures released inorganic phosphate from ATP. For all experi-
ments, the specific activity was determined using the equation of a 
standard line generated using phosphate standard (R&D Systems). 
Reaction mixtures contained 150 ng of GST–CdsN, 40 µM ATP, 
50 mM Tris–HCl pH 7.0, 5 mM MgCl
2
, and 10 mM KCl. The reac-
tion mixture (1 mL) was incubated at 37°C for 1 h and 50 µL of 
the mixture was taken for inorganic phosphate determination at 
various time points. The reaction was stopped by the addition of 
10 µL of Malachite Green Reagent A followed by 10 µL of Malachite 
Green Reagent B and incubated at room temperature for 1 min 
before an OD
610
 reading was taken, according to the manufacturer’s 
instructions. For the negative control, purified CdsN was digested 
for 10 min at 37°C using Proteinase K (Invitrogen). Also, as a nega-
tive control, another GST-tagged protein (CopN) that lacks ATPase 
activity was purified in the same manner and tested for activity. 
ATPase activity was expressed as nmol phosphate released min−1, 
and all experiments were performed in triplicate. His–CdsL was 
purified from Ni-NTA agarose beads and tested for any contami-
nating ATPase activity using the Malachite Green Assay. It was then 
added in varying amounts into the reaction mixture with CdsN 
prior to addition of ATP and incubated for 20 min on ice. The 
activity assay was then performed as described above.
gst pull-down assays
To examine the interaction of CdsN
221–270
 with CdsL, GST pull-
down assays were performed as described previously by Johnson 
et al. (2008), with the following modifications. Briefly, glutathione–
agarose beads (30 µL) bound to 50 ng of GST-tagged CdsN
221–270
 
protein was used in the assay. The beads were incubated overnight 
at 4°C with the E. coli lysate expressing the His-tagged proteins. 
The beads were collected by centrifugation and washed with 0.1% 
Triton X-100 and increasing concentrations of NaCl to elimi-
nate spurious protein interactions. The presence of the GST- and 
His-tagged proteins were confirmed by both Coomassie blue and 
Western blot. All proteins were eluted from the glutathione beads 
and electrophoresed on an 11% SDS–PAGE gel before being probed 
for His-tagged protein. GST alone bound to glutathione beads was 
used as a negative control for the pull-down.
peptIde lIbrary synthesIs, screenIng assays, and 3d ModelIng
The linear and/or CLIPS peptides are synthesized based on the 
amino acid sequence of the target protein using standard Fmoc-
chemistry and de-protected using trifluoric acid with scavengers. 
The constrained peptides are synthesized on chemical scaffolds in 
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above using cell monolayers on glass cover slips in shell vials, fixed 
in methanol, and stained using the Pathfinder kit, which uses 
a FITC-conjugated major outer membrane protein (MOMP)-
monoclonal antibody specific to Chlamydia, as per the manu-
facturer’s instructions.
results
regulatIon of cdsn by cdsl
Type III secretion ATPases are known to be enzymatically down-
regulated by YscL orthologs (Blaylock et al., 2006). C. pneumoniae 
encodes a YscL ortholog, CdsL (Cpn0826), which led us to explore 
whether CdsL down-regulates CdsN in C. pneumoniae. We have 
previously confirmed that CdsN interacted with CdsL using a GST 
pull-down assay, showing that CdsL co-purified with CdsN in 
500 mM NaCl (Stone et al., 2008). We also showed previously that 
a CdsN-GST fusion protein possessed enzymatic activity consist-
ent with other T3S ATPases (Stone et al., 2008). We found that 
CdsN hydrolyzed ATP at a rate of 0.0734 ± 0.0053 nmol/min at 
the concentration used in this assay (150 ng total). Prior to test-
ing the ability of CdsL to regulate CdsN activity, we confirmed 
that CdsL lacked any ATPase activity by assaying it alone in the 
malachite green assay to control for possible contamination and 
found that CdsL possessed no ATPase activity. To test for regu-
lation of CdsN by CdsL we added increasing amounts of CdsL 
to the CdsN reaction mixture. We found that addition of CdsL 
reduced CdsN enzymatic activity at a 0.3 CdsL:1 CdsN molar ratio, 
but the effect was most dominant at a 2.1 CdsL:1 CdsN molar 
ratio of CdsL: CdsN, where enzymatic activity was reduced by 
82% (Figure 1). Further increasing the CdsL concentration only 
marginally reduced activity. The addition of a control His-tagged 
protein (His-CopN, a T3S structural component) had no effect 
on CdsN activity. Also as a control, His–CdsL had no effect on the 
enzymatic activity of a second C. pneumoniae ATPase, GspE (data 
not shown). GspE is a type II secretion ATPase which possesses 
enzymatic activity.
pepscan analysIs of cdsn–cdsl InteractIon
We have shown that CdsN is enzymatically down-regulated by 
CdsL, but the mechanism by which this occurs is unknown. In an 
attempt to expand our understanding of how CdsL may function to 
down-regulate CdsN, we have utilized Pepscan epitope mapping to 
identify the domains within CdsN responsible for the CdsL inter-
action. Purified His–CdsL was added to an over-lapping peptide 
library consisting of 4000 over-lapping linear and conformational 
peptides of the CdsN protein in search for the peptide domain 
mediating protein binding (Timmerman et al., 2007). CdsN con-
tained two binding regions that mediated the interaction with CdsL. 
The two CdsL binding sequences spanned residues 221–229, and 
residues 265–270 corresponding to the amino acids “RSVIVVSTS” 
and “TRFARA,” respectively, both of which are present within the 
catalytic domain (Figure 2). To corroborate the Pepscan data, 
we cloned and expressed a fragment of CdsN spanning residues 
221–270 containing both of the CdsL predicted binding domains 
to test whether this CdsN fragment bound to His–CdsL. We found 
that the CdsN
221–270
 co-purified with His–CdsL in the presence of 
500 mM NaCl while GST alone did not co-purify with CdsL under 
any salt conditions (Figure 3).
The final peptide utilized was the 28-amino acid sequence 
YGRKKRRQRRRCVVLMMDSVTRFARALC and was used in its 
linear form for inhibition experiments. Peptides were synthesized 
by Peptide 2.0.
gst–Mts uptake by ebs
Chlamydial EBs were purified using a discontinuous gastrografin 
gradient, and resuspended in PBS. Either GST or GST–MTS was 
incubated at varying concentrations (0, 100, 500 µm) or for vary-
ing times (5, 30, or 60 min) with the purified EBs at 4°C. The EBs 
were then pelleted and washed three times with PBS, followed by 
trypsinization for 30 min to ensure that no protein was bound to 
the outside of the EB. EBs were then boiled in loading dye and 
probed for the presence of GST using Western blot.
peptIde cytotoxIcIty
The cytotoxicity was performed as described by Johnson et al. 
(2009). The effect of the CdsN TRFARA peptide on HeLa cell via-
bility was determined. Briefly, 50 or 100 µM of the CdsN peptide, 
control peptides, or the positive control (1% SDS plus 0.1% Triton 
X-100) were added to sub-confluent HeLa cells in six-well plates. At 
1 h supernatants were harvested and tested for the presence of ade-
nylate kinase using a cytotoxicity assay (Lonza ToxiLight® BioAssay, 
Rockland). The cytotoxicity assay was performed as per the manu-
facturer’s protocol. Briefly, supernatants from HeLa cell cultures 
incubated with the CdsN TRFARA peptide (in MEM containing 
cycloheximide) were tested for evidence of eukaryotic cell cytotox-
icity. Aliquots (5 µL) of each supernatant were mixed with 25 µL of 
Adenylate Kinase Detection Reagent and samples were incubated 
at room temperature for 5 min. Relative light units (RLUs) were 
measured using a 20/20-n Single Tube Luminometer from Turner 
BioSystems (Sunnyvale). Assays were conducted in triplicate for 
each condition. Cell monolayers were washed with warm PBS. 
0.75 mL of trypsin was added to each well, and 0.75 mL of MEM was 
added after complete trypsinization (trypsinization was monitored 
by light microscopy). Each sample was thoroughly resuspended and 
aliquoted into a plastic cuvette and the cell number immediately 
quantitated by determining the optical density at 800 nM using a 
spectrophotometer.
electron MIcroscopy and IMMunofluorescence
HeLa cells grown to 90% confluency in 6-well plates were infected 
with C. pneumoniae, pre-incubated with linear CdsN peptide 
for 30 min or with linear random peptide (MTS–MFAVNAQ) 
for 30 min at various concentrations, centrifuged for 45 min at 
room temperature, followed by incubation at 37°C for 1 h. The 
inoculum and peptide were removed and the medium replaced 
with MEM containing 1 µg/mL cycloheximide to inhibit host 
cell protein synthesis. Cells were incubated at 37°C for 72 h, 
collected by trypsinization and centrifugation at 1000 rpm for 
10 min then fixed overnight at 4°C with 2% glutaraldehyde (v/v) 
in cacodylate buffer, 7.2. The cell pellets were post-fixed in 2% 
osmium tetroxide (v/v), embedded in Spurs medium, and thin 
sections were cut on a Reichert Ultracut E microtome. Sections 
were examined in a Jeol 1200 electron microscope at 80 kV and 
pictures were captured with an AMT digital camera. For immun-
ofluorescent staining of inclusions, HeLa cells were infected as 
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MTS, YGRKKRRQRRR (Efthymiadis et al., 1998). We also extended 
the CdsN sequence flanking the TRFARA peptide to ensure the 
entire binding domain was included, and flanked the peptide with 
cysteine residues to assist with any disulfide bonding that may be 
required for binding. The final peptide utilized was the 28-amino 
acid sequence YGRKKRRQRRRCVVLMMDSVTRFARALC. To 
examine whether the peptide-MTS was entering EBs, we first incu-
bated either GST alone or GST–MTS at 50, 100, and 500 µM with 
gastrografin purified EBs. We saw that the amount of GST–MTS 
entering EBs increased in a dose-dependent manner (Figure 5A). 
The GST control (500 µm) was taken up poorly by Chlamydia. We 
then added either GST or GST–MTS for increasing time periods 
(5, 30, or 60 min) which showed increasing uptake with time, start-
ing as early as 5 min (Figure 5B). Again, the GST control showed 
very poor uptake into Chlamydia, suggesting that the MTS facili-
tates peptide entry in a time- and dose-dependent manner. HeLa 
cells were then infected with C. pneumoniae at an MOI of 2 and 
stained for inclusions at 72 h using a FITC-conjugated anti-MOMP 
monoclonal antibody. The CdsN peptide was added to EBs at a 0, 
20, 50, and 100-µM concentrations for 30 min prior to infection 
and we saw that infectivity was reduced in a dose–response fashion 
(Figure 6A). In the absence of the peptide, inclusions are clearly 
visible at 72 h (Figure 7). Pre-treatment of the cells with 50 µM 
peptide resulted in a drastic reduction in the number of inclusions 
(>95%), while at 100 µM there was toxicity for HeLa cells. To rule 
out the possibility that the inhibitory activity at 50 µM might be 
due to toxicity we tested the effect of the peptide at 50 µM on HeLa 
cells using an adenylate kinase release assay and found little or 
no toxicity (Figure 6B). We next examined infected cells with the 
CdsN or the random peptide by transmission electron microscopy. 
In infected cells exposed to the random peptide large inclusion 
bodies containing a mixture of RBs and EBs were readily visible 
3d ModelIng of cdsn–cdsl bIndIng doMaIn
The crystal structure of the E. coli T3S ATPase, EscN, has recently 
been elucidated, allowing us to use an orthology modeling approach 
to obtain a predicted 3D structure of CdsN and to visualize the CdsL 
binding domains (Zarivach et al., 2007). CdsN and EscN possess a 
large amount of sequence orthology within the catalytic domain, 
where the CdsL binding domains are located (Stone et al., 2008). 
Using 3D-JIGSAW, a 3D structure of CdsN was generated and used 
to model the binding domains for CdsL. Modeling of the binding 
regions of CdsL on the predicted CdsN monomer revealed that both 
of the binding domains for CdsL are present in the central region 
of CdsN (Figure 4A). A more revealing mapping of the binding 
domains is shown when hexameric CdsN is modeled from the EscN 
crystal structure (Zarivach et al., 2007). For clarity, we have shown 
only one half of the predicted hexameric structure of CdsN (a CdsN 
trimeric complex). Residues 221–229 are exposed toward the outer 
face of the hexamer (Figure 4B, blue), while residues 265–270 are 
exposed in the central channel of the hexameric ring (Figure 4C, 
red). The location of the binding domains is consistent with a pro-
posed mechanism of CdsL down-regulation of CdsN sterically hin-
dering access of ATP to the P-loop (Figures 4B,C, magenta).
InhIbItIon of C. pneumoniae growth and replIcatIon by cdsn 
cognate peptIde
The Pepscan binding data revealed two distinct domains of CdsN 
that mediate the interaction between CdsN and CdsL. Using this 
information we sought to design and utilize a peptide mimetic 
targeting the interaction between CdsN and CdsL and examine 
its effect on chlamydial replication. As discussed above, CdsN pos-
sessed two different binding domains for CdsL; we selected the 
six amino acid sequence TRFARA to create a potential peptide 
mimetic. We synthesized the TRFARA peptide with a N-terminal 
FIgure 1 | CdsL down-regulations CdsN enzymatic activity in a dose-
dependent fashion. Aliquots (150 ng) of GST–CdsN were assayed for 
enzymatic activity using the malachite green assay to detect released inorganic 
phosphate from ATP. His–CdsL was added to the reaction mixture at molar ratios 
between 0.3 and 2.1, and ATPase activity of GST–CdsN was measured. 
Increasing amounts of CdsL resulted in a decrease in CdsN enzymatic activity. 
The maximum reduction of activity was seen at a 2.1: CdsL:1 CdsN molar ratio 
(82% reduction in CdsN enzymatic activity). All experiments were performed in 
triplicate and data is presented as the mean with error bars representing 1 SD of 
the mean.
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FIgure 2 | Pepscan analysis of the CdsL binding domain on CdsN. An 
over-lapping peptide library for full length CdsN consisting of 4000 linear and 
looped peptides was constructed by Pepscan Presto (The Netherlands). 
His–CdsL was screened against the peptide library to identify CdsN peptides 
that interact with CdsL. (A) Raw Pepscan data obtained by screening full 
length His–CdsL against the over-lapping peptide library of 4000 linear and 
looped CdsN peptides (x-axis). The two distinct CdsL binding domains are 
highlighted in black within the vertical boxes, and the signal strength of the 
interaction is visualized on the y-axis. The two peaks correspond to the 
sequences RSVIVVSTS and TRFARA. (B) The two amino acid sequences to 
which CdsL binds (RSVIVVSTS and TRFARA) are bolded within the full length 
CdsN amino acid sequence.
FIgure 3 | The CdsN221–270 peptide, containing both the predicted 
CdsN–CdsL binding domains, co-purifies with CdsL. GST–CdsN221–270 was 
bound to glutathione beads and used to pull-down His–CdsL from Escherichia 
coli lysates. Beads were collected by centrifugation, washed with 0, 200, and 
500 mM NaCl and probed for His-tagged protein by Western blot using anti-His 
antibody. GST–CdsN221–270 co-purified with CdsL while GST alone did not.
while infected cells incubated with 50 µM CdsN peptide lacked 
any detectable inclusions when over 200 cells were examined and 
showed no evidence of cytotoxicity (Figure 7).
dIscussIon
Although C. pneumoniae contains all the genes coding for a T3SS, 
only a small number of these have been characterized. We have 
previously shown that CdsN possesses enzymatic activity and 
interacts with the putative type III secretion protein, CdsL (Stone 
et al., 2008). We have now extended these observations to show 
that CdsL functions to down-regulate CdsN enzymatic activity. We 
have also used a novel approach to map the exact region within 
CdsN that mediates the CdsN–CdsL interaction, and used this 
information to design a peptide mimetic that disrupts the chlamy-
dial replication cycle. Combined, this data provides new insights 
into the regulation of the T3S system and its importance in the 
chlamydial life-cycle.
YscL orthologs have been shown to down-regulate T3S ATPase 
enzymatic activity in Yersinia, and C. pneumoniae encodes a YscL 
ortholog (CdsL; Blaylock et al., 2006; Stone et al., 2008). We found 
that CdsN treated with increasing concentrations of CdsL reduced 
enzymatic activity up to 82%. To show that the regulation by CdsL 
was specific we tested the ability of CdsL to down-regulate the type 
II secretion ATPase of Chlamydia, GspE, and found that it had no 
effect on its enzymatic activity. This suggests that CdsL is specific 
in its down-regulation of CdsN. CdsL has previously been shown 
to be expressed at all time points throughout the replication cycle 
with an apparent accumulation during the final 48 h (Slepenkin 
et al., 2003). This is consistent with a role for CdsL regulating T3S 
during invasion and intracellular replication phases of the life-cycle 
in EBs and RBs, respectively.
Type III secretion ATPases are known to mediate numerous pro-
tein interactions between both structural components and chap-
erone/effector complexes, and play a critical role in construction 
of the injectisome and secretion of effectors (Gauthier and Finlay, 
2003; Akeda and Galan, 2005). We used Pepscan Analysis to deter-
mine the CdsN domain that mediates the interaction with CdsL. 
We found that there were two distinct domains within CdsN that 
interacted with CdsL; one exposed in the central channel of the 
hexameric structure of CdsN and the other exposed on the outer 
face. Using GST pull-downs, we corroborated the Pepscan data by 
demonstrating that a 49-amino acid fragment of CdsN containing 
both of the predicted CdsL binding domains was able to co-purify 
with full length CdsL. We have shown previously that CdsL forms 
dimers, and it is likely that the two CdsL molecules interact with 
different regions of CdsN (Pallen et al., 2006; Stone et al., 2008). 
This would be consistent with the two binding domains on CdsN. 
Along with regulating ATPase activity, CdsL is believed to tether the 
ATPase to the inner membrane, functioning in a similar manner as 
the gamma-stalk of the F
0
F
1
 ATPase which runs through the central 
channel of the F
0
F
1
 hexamer and may interact with the membrane 
(Pallen et al., 2006). The location of the CdsL binding domain within 
the central channel of CdsN supports the concept that CdsL func-
tions in a similar manner as the gamma-stalk domain for CdsN. 
Both binding domains are found in close proximity to the P-loop 
within the catalytic domain which coordinates ATP binding and 
cleavage (Stone et al., 2008). It is possible that when CdsL is bound 
to either of these domains it could sterically hinder access of ATP 
to the P-loop, reducing enzymatic function of CdsN. The tethering 
function of CdsL would be crucial for T3S function, and if this teth-
ering is mediated by the binding domain within the central chan-
nel of the CdsN hexamer then likely this interaction is maintained 
throughout the entire developmental cycle. The exposed binding 
domain on the outer surface of the CdsN hexamer, however, could 
be responsible for the down-regulation of CdsN by CdsL. CdsL could 
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and cellular invasion. We first confirmed that the MTS facilitated 
uptake of the peptide into EBs in a time- and dose-dependent 
manner. Afterward, we treated the chlamydial EBs for 30 min 
with the CdsN peptide which reduced chlamydial infection in a 
dose–response fashion, and at a concentration of 50 µM reduced 
Chlamydia infectivity by >95%, as determined by IF staining and 
counting of inclusions at 72 h. An alternative explanation of this 
data could be that the peptide was bactericidal toward Chlamydia, 
but we feel that this is unlikely since a random peptide failed to 
inhibit chlamydial replication. We have also shown that two addi-
tional peptide mimetics targeting other essential protein inter-
actions can also inhibit chlamydial replication (Mahony et al., 
2010). We are currently investigating whether the CdsN peptide 
mimetic can inhibit chlamydial replication if administered during 
the infection cycle, once infection has occurred, which if success-
ful would indicate that the peptide can disrupt CdsN–CdsL com-
plexes within RBs and block T3S across the inclusion membrane. 
This would suggest that ATPase activity is carefully regulated by 
CdsL in both EBs and RBs, and the CdsN–CdsL interaction is 
critical for chlamydial replication.
The discovery of unique CdsN binding domains for CdsL cou-
pled with structural modeling of the binding domains has allowed 
us to postulate how CdsL functions to down-regulate CdsN. This 
has allowed us to create a cognate CdsN peptide that functions 
as a novel antimicrobial agent, preventing C. pneumoniae from 
bind and dissociate from the outer CdsN–CdsL binding domain 
upon a conformational change in CdsN, thereby activating ATPase 
activity upon CdsL release by allowing ATP to access the P-loop. It 
is tempting to speculate that delivery of effector/chaperone com-
plexes to CdsN, possibly by a multi-cargo transport protein such as 
CdsQ, could be the trigger for CdsL release and ATPase activation, 
allowing for the dissociation of the effector/chaperone complex and 
subsequent secretion of the effector (Spaeth et al., 2009).
Using Pepscan epitope mapping we have shown where CdsL 
binds to CdsN. Using this binding data we designed a cognate 
CdsN peptide containing a membrane transport signal to allow 
the peptide to enter Chlamydia and showed that this peptide 
blocked chlamydial invasion of HeLa cells. Membrane transport 
signals are known to interact hydrophobically with eukaryotic 
membranes, triggering entry by endocytosis across the mem-
brane (Efthymiadis et al., 1998). Our working hypothesis is that 
this transport signal would facilitate entry of the CdsN peptide 
into EBs, and that this could potentially disrupt the CdsN–CdsL 
interaction and inhibit T3S, and thus invasion, although we have 
not shown inhibition of T3S per se. This could be achieved by 
either disrupting the regulation of the ATPase or interfering with 
the tethering function of the ATPase, displacing its peripheral 
association with the inner membrane. Either of these two sce-
narios could disrupt the T3SS, preventing chlamydial infection 
FIgure 5 | uptake of a gST-Membrane transport signal (MTS) fusion 
protein into eBs. EBs were purified on a discontinuous gastrografin gradient 
and collected by centrifugation to ensure the use of a homogenous EB 
mixture. The GST alone and GST–MTS protein was expressed in Escherichia 
coli cells and purified using glutathione beads. The EBs were then incubated 
with either GST or GST–MTS, trypsinized for 30 min to ensure that all 
extracellular GST or GST–MTS was degraded, and examined by α-GST 
Western blot for the presence of intracellular GST-tagged protein. CdsL, an 
intracellular type III secretion protein, was used as a loading control (LC). (A) 
Time-course for incubation of EBs with GST–MTS for 5, 30, or 60 min. GST 
control at 60 min displayed very little protein while GST–MTS at 5, 30, and 
60 min had increasing amounts of GST–MTS present within the EBs. (B) 
Dose–response of EBs incubated with GST–MTS at 50, 100, and 500 μm. GST 
control at 500 μm displayed very little protein while GST–MTS accumulated 
within the EBs as the concentration increased. CdsL is shown as a LC.
FIgure 4 | CdsL binding domains mapped onto the predicted 3D 
structure of CdsN reveals two distinct domains. A 3D structure of CdsN 
was generated based on orthology modeling using 3D-JIGSAW based on the 
structure of EscN, and used to visualize the CdsL binding domains identified 
from – 30 – the peptide library binding data. The two CdsL binding domains on 
CdsN are in blue (residues 221–229) or red (residues 265–270), and the ATP 
coordinating P-loop region of CdsN is highlighted in magenta. (A) 
Representation of the predicted CdsN monomeric structure indicating both 
CdsL binding domains (RSVIVVSTS in blue, TRFARA in red). (B) Structural 
model showing the location of residues 221–229 (RSVIVVSTS), displayed on 
one half of the predicted hexameric structure and viewed from the outer face, 
revealing that the binding domains are exposed to the outside of the hexamer. 
The P-loop is represented in magenta. (C) Structural model viewed from 
outside looking toward the central channel showing the location of residues 
265–270 (TRFARA), displayed on one half of the predicted hexameric structure 
revealing that the domain is exposed within the central channel. The P-loop is 
represented in magenta.
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FIgure 6 | CdsN peptide containing the CdsL binding sequence TrFArA 
inhibits the infection of HeLa cells in a dose-dependent fashion and shows 
low toxicity at 50 μM. Shell vials grown to 85% confluency were infected with 
Chlamydia pneumoniae at an MOI of 3 after incubation with the CdsN or control 
peptide. Infected cells were counted by staining with a Chlamydia specific major 
outer membrane protein (MOMP)-monoclonal antibody (Pathfinder kit). Toxicity 
was measured using an adenylate kinase release assay for HeLa cells in the 
presence of either the CdsN or control peptide. (A) CdsN peptide was added at 
increasing concentrations (20, 50, and 100 μM) and demonstrated a dose–
response in reduction of C. pneumoniae infectivity of HeLa cells. The control 
represents a random peptide with the sequence MFAVNAQ–MTS that had no 
effect on C. pneumoniae infectivity. All experiments were performed in triplicate 
and data is presented as the mean with error bars representing the mean + 1 
SD with **representing p < 0.01. (B) Toxicity of the CdsN peptides toward HeLa 
cells was evaluated using the Lonza adenylate kinase release assay. The CdsN 
peptide was added to HeLa cells for 1 h at 50 and 100 μM, and the random 
peptide was added for 1 h at 100 μM. We saw that the CdsN peptide at 50 μM 
had no toxicity toward HeLa cells, and only minor toxicity at 100 μM.
FIgure 7 | CdsN peptide reduces chlamydial infectivity of HeLa cells by 
IF staining and eM. HeLa cells were pretreated with CdsN or a control 
peptide (MTS–MFAVNAQ), then infected with Chlamydia pneumoniae at an 
MOI of 3 and examined by either IF staining using anti-MOMP monoclonal 
antibody treatment with the pathfinder kit (top) or by electron microscopy 
(bottom). (A) HeLa cells treated with the control peptide (100 μM) and 
infected with C. pneumoniae. Immunofluorescent staining reveals numerous 
infected cells (top) while electron microscopy reveals a large inclusion body 
with both EBs and RBs (bottom). (B) HeLa cells treated with the CdsN peptide 
(50 μM) and infected with C. pneumoniae. Evaluation of over 200 cells treated 
with the CdsN peptide by IF staining and EM examination revealed a drastic 
reduction in C. pneumoniae infected cells and a complete lack of detectable 
inclusions by EM.
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